Mink Therapeutics Inc INKT
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-10-15 |
| Shares Out. | 4,980,000 |
| Website | minktherapeutics.com ↗ |
| Phone | 12129948250 |
| Employees | 15 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$3.1M |
| Free Cash Flow | -$6.8M |
| Total Assets | $9.6M |
| Total Liabilities | $23.6M |
| Equity | -$14.0M |
About Mink Therapeutics Inc
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
Mink Therapeutics Inc is a publicly traded company under the ticker symbol INKT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-09-01)